Loading
Nina Bhardwaj is a dendritic-cell immunologist running personalised neoantigen vaccine trials.
Nina Bhardwaj is Director of Immunotherapy and holds the Ward-Coleman Chair in Cancer Research at The Mount Sinai Hospital and Tisch Cancer Institute. She is a dendritic cell immunologist and a pioneer of dendritic cell biology in human immunity. She leads the PGV001 personalised neoantigen peptide vaccine programme, and her selected paper reports a phase 1 trial of the safety and immunogenicity of a multi-peptide personalised genomic vaccine as adjuvant treatment of solid cancers. Her current work spans personalised neoantigen vaccines and off-the-shelf cancer vaccines.
| Title | Journal | Year |
|---|---|---|
| A phase I trial of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid cancers | Cancer Discovery | 2024 |
Shares The Mount Sinai Hospital / Tisch Cancer Institute, Off-the-shelf cancer vaccines.
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
Shares Neoantigen, Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.